Bright Minds Biosciences (DRUG) Common Equity (2019 - 2026)

Bright Minds Biosciences (DRUG) has 7 years of Common Equity data on file, last reported at $225.0 million in Q1 2026.

• Quarterly Common Equity rose 479.14% year-over-year to $225.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $225.0 million (up 479.14% YoY) and the FY2025 annual result came in at $59.6 million, up 1368.96% from the prior year.
• Common Equity climbed to $225.0 million in Q1 2026, from $64.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $225.0 million in Q1 2026 to a low of $4.1 million in Q3 2024.
• A 5-year average of $31.3 million and a median of $8.1 million in 2022 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity tumbled 62.86% — and 2025, when it jumped 1368.96%.
• Tracing DRUG's Common Equity over 5 years: stood at $8.1 million in 2022, then plunged by 45.15% to $4.4 million in 2023, then jumped by 834.14% to $41.4 million in 2024, then jumped by 54.66% to $64.0 million in 2025, then soared by 251.42% to $225.0 million in 2026.
• The last three Common Equity figures came in at $225.0 million (Q1 2026), $64.0 million (Q4 2025), and $59.6 million (Q3 2025), per Business Quant data.